Fig. 7: Vit-B6 confers protection by facilitating Kyn catabolism.
a Plasma PLP levels in the lean subjects (18 ≤ BMI < 24, n = 354), subjects with overweight (24 ≤ BMI < 28, n = 268) and subjects with obesity (BMI ≥ 28, n = 113). b Plasma PLP levels in WT mice fed with a 12-week of NCD or HFD (n = 25). c eWAT PLP levels in WT mice fed with a 12-week of NCD or HFD (n = 10). d Western blot results for p-STAT3Tyr705/STAT3 and AhR in mature adipocytes with indicated treatments (n = 3 independent experiments). e ELISA analysis of IL-6 in the culture supernatants of adipocytes with indicated treatments. f Bodyweight of HFD fed mice and HFD + B6 fed mice (n = 8). GTT (g) and ITT (h) measured in HFD fed mice and HFD + B6 fed mice (n = 8). PLP (i) and Kyn (j) levels in eWAT (left) and plasma (right) of mice in the HFD group and HFD + B6 group (n = 8). k RT-qPCR results for Ahr, Stat3 and Il-6 in eWAT of mice from HFD group and HFD + B6 group (n = 6). l Western blot results for p-STAT3Tyr705/STAT3 and AhR in eWAT of mice from HFD group and HFD + B6 group. m Western blot for p-AKTSer473 and AKT in eWAT of mice from HFD group and HFD + B6 group (n = 6). Data were represented as mean ± SEM. Statistical significance was assessed by one-way ANOVA (a, e), two-sided Student’s t test (b, c, i, j, k, l and m) and two-way ANOVA followed with Bonferroni’s multiple comparisons test (f, g and h) and significant differences were indicated with p values. Source data are provided in the Source Data file.
